U.S. markets closed

CASI Pharmaceuticals, Inc. (CASI)

NasdaqCM - NasdaqCM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
3.6100+0.6100 (+20.33%)
Al cierre: 04:00PM EDT
3.6400 +0.03 (+0.83%)
Fuera de horario: 06:48PM EDT

CASI Pharmaceuticals, Inc.

1701-1702, China Central Office Tower 1
No. 81 Jianguo Road Chaoyang District
Beijing 100025
China
86 10 6508 6063
https://www.casipharmaceuticals.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo224

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Wei-Wu He Ph.D.Chairman & CEO565.36kN/D1965
Dr. Wei Zhang Ph.D.President1.13MN/D1960
Dr. Alexander A. Zukiwski M.D.Executive VP & Chief Medical Officer514.79kN/D1957
Ms. Kun QianVP & Global ControllerN/DN/D1982
Ms. Chunhua WangChief Operating OfficerN/DN/D1972
Ms. Wei GaoGeneral CounselN/DN/D1981
Dr. James E. Goldschmidt Ph.D.Chief Business Development OfficerN/DN/DN/D
Mr. Hai HuangGlobal Chief Commercial OfficerN/DN/DN/D
Ms. Amanda CuiVP & Global ControllerN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Gestión corporativa

La calificación ISS Governance QuickScore de CASI Pharmaceuticals, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.